Trade AGEN

Agenus Inc

00:00:00

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Name	Sell	1D Chg
SMTC Semtech Corp	74.97	-4.065%
FDX Fedex	274.80	0.620%
NIO NIO Limited	4.370	-1.429%
DOYU DouYu International Holdings Ltd - ADR	15.910	2.893%
DVMT Dell Technologies Inc	109.81	-0.729%
TSLA Tesla Motors	426.76	-2.027%

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage.

The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Account Base Currency

Instrument

Volume in Lots (Contract Size 100,000)

Price

Long Buy Short Sell

Set Stop Loss Amount :

Set Profit Amount :

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss.

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value.

The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate